Lung cancer cells are inhibited depending on
the concentration of cordycepin.
The potential to become an anticancer agent was discovered.
The product containing cordyceps (Ara 301) was
confirmed to have sleep-inducing effects.
Can be used as a functional food and pharmaceutical agent for sound sleep
Strong Anticancer Agent, Cordyceps, that Selectively Targets Cancer Cells
Target Diseases: Colon cancer, breast cancer, lung cancer
Targets colon cancer, lung cancer and breast cancer, which account for the highest indicence in the modern society
Adverse event of existing anticancer drugs
The symptom and severity of anticancer drugs’ adverse events
vary depending on the treatment method
and individual characteristics of the patient
Cause multiple-drug resistance
To selectively kill cancer cells without influencing existing cells
No multiple drug resistance
Next-generation Anticancer Drug - Anticancer Drug, Antibiotics without Resistance
Reason for failed anticancer treatment due to chemotherapy
→ “causing multiple-drug resistance”
What is multi-drug resistance?
→ A phenomenon in which a cancer patient develops resistance to anticancer drugs with completely different structures
or mechanisms and thereby inhibits their therapeutic effects after receiving an anticancer drug
→ Efflux transporters such as p-glycoprotein (P-gp), Breast Cancer Resistance Protein (BCRP) are overexpressed in cancer cells,
increasing the excretion of anticancer drugs from cancer cells.
Multi-drug Resistance Problem of Anticancer Drugs
Anticancer adjuvants that can be administered in combination with anticancer drugs by inhibiting P-gp and BCRP is needed
03Anticancer adjuvants that can be administered in combination with anticancer drugs by inhibiting P-gp and BCRP is needed